Literature DB >> 22423122

Editorial commentary: Closing the loop--a colistin clinical study to confirm dosing recommendations from PK/PD modeling.

Jason A Roberts1, Jeffrey Lipman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22423122     DOI： 10.1093/cid/cis311

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  8 in total

Review 1.  Clinical implications of antibiotic pharmacokinetic principles in the critically ill.

Authors:  Andrew A Udy; Jason A Roberts; Jeffrey Lipman
Journal:  Intensive Care Med       Date:  2013-09-18       Impact factor: 17.440

Review 2.  A review on colistin nephrotoxicity.

Authors:  Atefeh Ordooei Javan; Shervin Shokouhi; Zahra Sahraei
Journal:  Eur J Clin Pharmacol       Date:  2015-05-27       Impact factor: 2.953

Review 3.  Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes.

Authors:  Laurent Poirel; Aurélie Jayol; Patrice Nordmann
Journal:  Clin Microbiol Rev       Date:  2017-04       Impact factor: 26.132

4.  New colistin population pharmacokinetic data in critically ill patients suggesting an alternative loading dose rationale.

Authors:  N Grégoire; O Mimoz; B Mégarbane; E Comets; D Chatelier; S Lasocki; R Gauzit; D Balayn; P Gobin; S Marchand; W Couet
Journal:  Antimicrob Agents Chemother       Date:  2014-09-29       Impact factor: 5.191

5.  DALI: Defining Antibiotic Levels in Intensive care unit patients: a multi-centre point of prevalence study to determine whether contemporary antibiotic dosing for critically ill patients is therapeutic.

Authors:  Jason A Roberts; Jan J De Waele; George Dimopoulos; Despoina Koulenti; Claude Martin; Philippe Montravers; Jordi Rello; Andrew Rhodes; Therese Starr; Steven C Wallis; Jeffrey Lipman
Journal:  BMC Infect Dis       Date:  2012-07-06       Impact factor: 3.090

Review 6.  Treatment for infections with carbapenem-resistant Enterobacteriaceae: what options do we still have?

Authors:  Michele Yamamoto; Aurora E Pop-Vicas
Journal:  Crit Care       Date:  2014-06-27       Impact factor: 9.097

7.  Activities of Cefiderocol with Simulated Human Plasma Concentrations against Carbapenem-Resistant Gram-Negative Bacilli in an In Vitro Chemostat Model.

Authors:  Shuhei Matsumoto; Sachi Kanazawa; Takafumi Sato; Yoshinori Yamano
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

8.  Nephrotoxicity of High and Conventional Dosing Regimens of Colistin: A Randomized Clinical Trial.

Authors:  Atefeh Ordooei Javan; Shervin Shokouhi; Zahra Sahraei; Jamshid Salamzadeh; Saeed Azad Armaki
Journal:  Iran J Pharm Res       Date:  2017       Impact factor: 1.696
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.